By Neurolixis, Inc. Neurolixis Inc. has been awarded funds by the US Department of Defense to test its drug candidate, NLX-112, in a preclinical model of Machado-Joseph disease (MJD), a rare and disabling inherited movement disorder.
|
By Neurolixis Inc. The Neurolixis lead compound, NLX-112, is at the heart of a brain imaging investigation of functionally-active serotonin 5-HT1A receptors in humans. NLX-112, a.k.a.
|
By Neurolixis, Inc. The US Food and Drug Administration (FDA) gave a positive response to Neurolixis' Investigational New Drug (IND) application for NLX-112.
|
By Neurolixis Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in developing novel drug formulations.
|
 | By Fighting Parkinson's Drug Free Howard Shifke knows a thing or two about Parkinson's disease. In his book "Fighting Parkinson's...and Winning: A memoir of my recovery from Parkinson's Disease," Shifke recounts the story of his developing Parkinson's, getting diagnosed, and his daily...
|
By Parkinson's Foundation TheParkinson's Foundation is hosting its Annual Celebrate Spring New Yorkevent, whichwill take place on Wednesday, April 11, 2018 at Lavo located at 39 East 58th Street between Madison and Park Avenues.
|
